Two experimental approaches are showing promise for the treatment of heart failure due to dilated cardiomyopathy: gene therapy and stem cell therapy. Both of these approaches have received a lot of publicity, and you may be wondering how close they are to routine clinical use.

The answer is that they are both in the very early stages of investigation, and a lot more work has to be done before they become widely available.

In animal experiments, several genes have been tried, including genes for sarcoplasmic reticulum (a membrane within muscle cells that helps to control calcium movement); for adrenaline receptors (receptors on cell membranes that allow cells to respond to adrenaline); and for adenylyl cyclase (a protein that helps to generate energy within cells).

While the animal testing of gene therapy has shown significant promise, it has not yet become advanced enough to proceed to clinical trials.

Based on such promising findings, early stem cell therapy has now been applied, in a few small studies, in carefully selected patients.

Early human studies suggest that the transplanted stem cells do not actually take over the work of the heart, but rather, they produce certain substances (including cytokines, growth factors, and others) that help the "native" heart cells to function more efficiently. They also appear to stimulate "native" stem cells already present in the heart to differentiate into functioning cardiac cells.

There has been only a very limited experience so far using stem cells in patients with heart failure. The small studies that have been done suggest that stem cells can modestly improve cardiac function in certain patients with dilated cardiomyopathy. This improvement is shown by an improvement in the ejection fraction.

Potential risks of stem cell therapy include the possibility of ventricular tachycardia, which apparently is seen in many patients after the injection of stem cells. Because of this problem, some investigators now require patients to receive implantable defibrillators prior to certain types of stem cell therapy for heart failure. Also, observations suggest that in patients who have stents for coronary artery disease, restenosis (blockage) may be more frequent after stem cell treatment.

In summary, stem cell therapy for heart failure is still in its early stages of investigation. Major questions remain regarding what types of cells are best to use, how they should be delivered, how likely it is that there will be a significant long-term benefit, and whether the long-term safety of the technique is acceptable. While stem cell therapy has shown promise, investigators are still quite a ways from being ready for a major clinical trial, let alone for routine usage.

Sources:

Read more:
Gene Therapy and Stem Cell Therapy For Heart Failure

BONE MARROW TRANSPLANTATION OVERVIEW

Bone marrow transplantation (BMT), also called hematopoietic stem cell transplant or hematopoietic cell transplant, is a type of treatment for cancer (and a few other conditions as well). A review of the normal function of the bone marrow will help in the understanding of bone marrow transplantation.

Bone marrow functionBone marrow is the soft, spongy area in the center of some of the larger bones of the body. The marrow produces all of the different cells that make up the blood, such as red blood cells, white blood cells (of many different types), and platelets. All of these cells develop from a type of precursor cell found in the bone marrow, called a hematopoietic stem cell.

The body is able to direct hematopoietic stem cells to develop into the blood components needed at any given moment. This is a very active process, with the bone marrow producing millions of different cells every hour. Most of the stem cells stay in the marrow until they are transformed into the various blood components, which are then released into the blood stream. Small numbers of stem cells, however, can be found in the circulating blood, which allows them to be collected under certain circumstances. Various strategies can be employed to increase the number of hematopoietic stem cells in the blood prior to collection. (See 'Peripheral blood' below.)

Bone marrow transplantationSome of the most effective treatments for cancer, such as chemotherapy and radiation, are toxic to the bone marrow. In general, the higher the dose, the more toxic the effects on the bone marrow.

In bone marrow transplantation, you are given very high doses of chemotherapy or radiation therapy, which is intended to more effectively kill cancer cells and unfortunately also destroy all the normal cells developing in the bone marrow, including the critical stem cells. After the treatment, you must have a healthy supply of stem cells reintroduced, or transplanted. The transplanted cells then reestablish the blood cell production process in the bone marrow. Reduced doses of radiation or chemotherapy that do not completely destroy the bone marrow may be used in some settings. (See 'Non-myeloablative transplant' below.)

The cells that will be transplanted can be taken from the bone marrow (called a bone marrow transplant), from the bloodstream (called a peripheral blood stem cell transplant, which requires that you take medication to boost the number of hematopoietic stem cells in the blood), or occasionally from blood obtained from the umbilical cord at the time of birth of a normal newborn (called an umbilical cord blood transplant).

TYPES OF BONE MARROW TRANSPLANTATION

There are two main types of bone marrow transplantation: autologous and allogeneic.

Autologous transplantIn autologous transplantation, your own hematopoietic stem cells are removed before the high dose chemotherapy or radiation is given, and they are then frozen for storage and later use. After your chemotherapy or radiation is complete, the harvested cells are thawed and returned to you.

See the original post here:
Bone marrow transplantation (stem cell transplantation)

Browse Articles & Videos By Category

Jacquelyn Jeanty

Jacquelyn Jeanty has worked as a freelance writer since 2008. Her work appears at various websites. Her specialty areas include health, home and garden, Christianity and personal development. Jeanty holds a Bachelor of Arts in psychology from Purdue University.

Since 1968, bone-marrow transplant procedures have been used to treat diseases such as leukemia, lymphomas and immune-deficiency disorders. By comparison, stem-cell transplants procedures are a fairly new development within the medical-science world. As a result, the potential uses and risks involved with stem-cell procedures are as of yet not fully known.

Transplant procedures are intended to replace defective or damaged tissues and cells with cells that are able to replace damaged tissue and restore normal function within the body. The use of bone-marrow material versus stem cell material is actually referring to two sides of the same coin, as bone marrow is a type of stem cell derived from the cells inside the bone. Stem cells, in general, can be taken from a number of sources, some of which include the umbilical cord, fetal material, the placenta, somatic cells, embryonic materials, as well as bone marrow material. The type of transplant procedure used will depend on the type of treatment needed and the area of the body affected.

Stem-cell research is a developing field in which stem cells are used to cure diseases, engineer gene-types and clone animals and humans. What makes stem cells so promising is their ability to evolve into a variety of different tissue forms. When used to treat diseased tissues, stem cells may provide a permanent cure as healthy new cells reproduce and replace defective cell organisms. This type of transplant may someday provide a way to treat cancer formations inside the body. Bone marrow stem cells are being used to replace unhealthy bone marrow in people who suffer from blood-borne diseases such as leukemia.

As with any type of surgical procedure, certain risks are involved when undergoing a stem-cell transplant. Frequent testing and possible hospitalizations may be necessary after the procedure is done. Individuals who receive donor stem cells may experience what's called the "graft-versus-host disease." This condition occurs when the patient's immune system reacts to the transplanting of donor stem cells. Symptoms of graft-versus-host disease include vomiting, diarrhea, skin rashes and abdominal pain. Organ damage, blood vessel damage and secondary cancers are other possible complications that can arise.

Bone-marrow material is made up of the soft tissue contained inside the bones. This material is responsible for producing and storing the body's blood cells. Bone marrow can be extracted from the breast bone, the hips, the spine, the ribs and the skull. Transplant materials can be used to replace unhealthy bone material for individuals who've undergone radiation or chemotherapy treatments. Individuals who suffer from a genetic disease such as Hurler's syndrome or adrenoleukodystrophy can also benefit from receiving a healthy supply of bone-marrow material.

The risks involved with bone marrow transplants vary depending on how healthy a person is, the type of transplant being done and how compatible a donor's material is. Individuals who've undergone chemotherapy or radiation treatments may experience complications because of the weakened state that the body is in. As bone-marrow material can come from the patient or from a donor, compatibility risks are more of a concern when donor materials are used. Possible complications from a transplant include anemia, infection, internal bleeding or internal-organ damage.

There are different types of bone marrow transplants, including an allogeneic and an autologous transplant. In allogeneic bone marrow transplants, stem cells...

See the original post here:
Stem - Cell Transplant Vs. Bone - Marrow Transplant | eHow

Watch the Cancer.Net Video: Bone Marrow and Stem Cell Transplantation: An Introduction, with Sonali Smith, MD, adapted from this content.

Key Messages:

Stem cell transplantation is a procedure that is most often recommended as a treatment option for people with leukemia, multiple myeloma, and some types of lymphoma. It may also be used to treat some genetic diseases that involve the blood.

During a stem cell transplant diseased bone marrow (the spongy, fatty tissue found inside larger bones) is destroyed with chemotherapy and/or radiation therapy and then replaced with highly specialized stem cells that develop into healthy bone marrow. Although this procedure used to be referred to as a bone marrow transplant, today it is more commonly called a stem cell transplant because it is stem cells in the blood that are typically being transplanted, not the actual bone marrow tissue.

The purpose of bone marrow and hematopoietic (blood-forming) stem cells

Bone marrow produces more than 20 billion new blood cells every day throughout a person's life. The driving force behind this process is the hematopoietic (pronounced he-mah-tuh-poy-ET-ick) stem cell. Hematopoietic stem cells are immature cells found in both the bloodstream and bone marrow. These specialized cells have the ability to create more blood-forming cells or to mature into one of the three different cell types that make up our blood. These include red blood cells (cells that carry oxygen to all parts of the body), white blood cells (cells that help the body fight infections and diseases), and platelets (cells that help blood clot and control bleeding). Signals passing from the body to the bone marrow tell the stem cells which cell types are needed the most.

For people with bone marrow diseases and certain types of cancer, the essential functions of red blood cells, white blood cells, and platelets are disrupted because the hematopoietic stem cells dont mature properly. To help restore the bone marrows ability to produce healthy blood cells, doctors may recommend stem cell transplantation.

Types of stem cell transplantation

There are two main types of stem cell transplantation:

Autologous transplantation (AUTO). A patient undergoing an AUTO transplant receives his or her own stem cells. During the AUTO transplant process, the patients stem cells are collected and then stored in a special freezer that can preserve them for decades. Usually the patient is treated the following week with powerful doses of chemotherapy and/or radiation therapy, after which the frozen stem cells are thawed and infused into the patient's vein. The stem cells typically remain in the bloodstream for about 24 hours until they find their way to the marrow space, where they grow and multiply, beginning the healing process.

More here:
What is Stem Cell/Bone Marrow Transplantation? | Cancer.Net

Royal L #39;Opulent Rejuv
Rejuvenate your skin through the activation of skin stem cells. Brightens your skin for a more even toned complexion, restores skins natural moisture to serv...

By: SariSariNZ

See the article here:
Royal L'Opulent Rejuv - Video

The advance could lead to tissue-transplant operations for a range of debilitating disorders, such as Parkinson's disease, multiple sclerosis, heart disease and spinal cord injuries.

Last year, a team created stem cells from the skin cells of babies, but it was unclear whether it would work in adults.

However, a team of scientists from the Research Institute for Stem Cell Research at CHA Health Systems in Los Angeles and the University of Seoul said they had achieved the same result with two men, one aged 35, the other the 75-year-old. "The proportion of diseases you can treat with lab-made tissue increases with age. So if you can't do this with adult cells it is of limited value," said Robert Lanza, co-author of the research, which was published in the journal Cell Stem Cell.

The technique works by removing the nucleus from an unfertilised egg and replacing it with the nucleus of a skin cell. An electric shock causes the cells to divide until they form a "blastocyst", a small ball of a few hundred cells.

In IVF, a blastocyst is implanted into the womb, but with the new technique the cells would be harvested to create other organs or tissues.

The breakthrough is likely to reignite the debate about the ethics of creating human embryos for medical purposes and the possible use of the same technique to produce cloned babies - which is illegal in Britain.

Although the embryos created may not produce a human clone even if implanted in a womb, the prospect is now closer. However, scientists have tried for years to clone monkeys and have yet to succeed.

Dr Lanza admitted that without strong regulations, the early embryos produced in therapeutic cloning "could also be used for human reproductive cloning, although this would be unsafe and grossly unethical". However, he said it was important for the future of regenerative medicine that research into therapeutic cloning should continue.

Shoukhrat Mitalipov, a reproductive biologist from Oregon Health and Science University, who developed the technique last year, said: "The advance here is showing that [nuclear transfer] looks like it will work with people of all ages.

"I'm happy to hear that our experiment was verified and shown to be genuine."

Go here to see the original:
Cloning advance means human tissues could be regrown, even in old age

Lawrence LeBlond for redOrbit.com Your Universe Online

Invasive bladder cancer (IBC), a malignant disease that currently affects more than 375,000 people worldwide, has been found to be caused by a single type of cell in the lining of the bladder, according to researchers with the Stanford University School of Medicine.

The researchers say this is the first study to pinpoint the normal cell type that can give rise to IBC. It is also the first study to show that most bladder cancers and their precancerous lesions arise from just one cell, which could also explain why many bladder cancers recur after therapy.

Weve learned that, at an intermediate stage during cancer progression, a single cancer stem cell and its progeny can quickly and completely replace the entire bladder lining, Philip Beachy, PhD, professor of biochemistry and of developmental biology, said in a statement. All of these cells have already taken several steps along the path to becoming an aggressive tumor. Thus, even when invasive carcinomas are successfully removed through surgery, this corrupted lining remains in place and has a high probability of progression.

Beachy and colleagues found that while cancer stem cells and the precancerous lesions they form express an important signaling protein known as sonic hedgehog, the cells of subsequent invasive cancers invariably do not a critical switch that appears vital for invasion and metastasis. This switch may explain certain confusing aspects of previous studies on the cellular origins of bladder cancer in humans. It also pinpoints a possible weak link in cancer progression that could be targeted by therapies.

This could be a game changer in terms of therapeutic and diagnostic approaches, said Michael Hsieh, MD, PhD, assistant professor of urology and a co-author of the study. Until now, its not been clear whether bladder cancers arise as the result of cancerous mutations in many cells in the bladder lining as the result of ongoing exposure to toxins excreted in the urine, or if its due instead to a defect in one cell or cell type. If we can better understand how bladder cancers begin and progress, we may be able to target the cancer stem cell, or to find molecular markers to enable earlier diagnosis and disease monitoring.

Bladder cancer is the fourth most common cancer in men and the ninth in women. There are two main types of bladder cancer: one that invades the muscle around the bladder and then metastasizes to other organs, and another that remains confined to the bladder lining. Unlike noninvasive cancers, most invasive bladder cancers are untreatable. Those that can be treated are expensive and difficult to cure, and with a high likelihood of recurrences, ongoing monitoring is required.

To determine what genes or cell types are at play in the formation of bladder cancer, the study team used a mouse model that closely mimicked what happens in humans. Usually, researchers rely on prior knowledge or guesses as to what genes are involved and often genetically alter cell types in animals to induce overexpression of a gene known to be involved in tumorigenesis or to block the expression of a gene that inhibits cancer development.

LINK TO SMOKING

Previous work by Beachy and his colleagues suggested that basal cells play a role in bladder cancer. However, the new study offered an unbiased approach.

Continued here:
Single Cell Type Found To Cause Most Invasive Bladder Cancers: Study

Madison #39;s Before After Stem Cell Therapy
Had step cell therapy procedure on 4/14/14 and we were seeing noticeable results only 4 short days later.

By: Jaie Locke

Read more:
Madison's Before & After Stem Cell Therapy - Video

Phoenix, Arizona (PRWEB) April 21, 2014

The Center for Joint Regeneration is now offering several stem cell procedures for patients with knee arthritis to help avoid the need for joint replacement. The procedures are offered by Board-certified and Fellowship-trained orthopedic doctors, with the stem cells being derived from either bone marrow or amniotic fluid. For more information and scheduling with the top stem cell providers in the greater Phoenix area, call (480) 466-0980.

For the hundreds of thousands of individuals who undergo a knee replacement every year, it should be considered an absolute last resort, after other conservative options have failed. Although the vast majority of knee replacements do well, the implants are not meant to last forever, the surgery does have potential risks and the biomechanics of the knee are significantly changed with the prosthetic implants.

Stem cells for knee arthritis have the potential to repair and regenerate damage from arthritis and relieve pain substantially. Center for Joint Regeneration offers these outpatient procedures with several methods.

The first involves usage of the patient's own bone marrow, with a short harvesting procedure, processing the bone marrow, and injection at the same setting into one or both knees.

Another method is with amniotic derived stem cell rich material, which not only possesses concentrated stem cells but also a significant amount of growth factors and hyaluronic acid. The material is a meteorologically privileged and has been used tens of thousands of times around the world with minimal adverse events.

Platelet rich plasma therapy for knee degeneration is also offered. PRP therapy has been shown in recent studies at Hospital for Special Surgery to work well for pain relief from knee arthritis. It also offers the ability to preserve knee cartilage based on serial MRI's performed in the study.

So far, clinical outcomes with the stem cell regenerative procedures have been excellent. The Board-Certified orthopedic doctors at Center for Joint Regeneration, Doctors Farber and Dewanjee, are exceptionally well trained and highly skilled at these outpatient procedures.

For those individuals looking to avoid or delay the need for knee replacement due to degenerative arthritis, call the Center for Joint Regeneration today at (480) 466-0980. The Center offers stem cell treatments Phoenix and Scottsdale trust!

See the article here:
Center for Joint Regeneration Now Offering Several Stem Cell Procedures for Patients to Avoid Knee Replacement

Phoenix, Arizona (PRWEB) April 21, 2014

The top foot and ankle specialists in Arizona at Valley Foot Surgeons are now offering stem cell treatments for diabetic wounds. The treatments may propel these difficult wounds to heal in a much shorter time frame than they would without regenerative medicine therapy. The stem cell doctor is a four-time Phoenix Magazine Top Doc Winner; call (480) 994-5977 for more information and scheduling.

With up to a third of individuals suffering from diabetes (or pre-diabetes), wounds and ulcers are becoming more common all the time in the foot and ankle area. Due to the immunocompromised state of diabetics, it can be extremely difficult for the human body to naturally heal these wounds. Sometimes, they persist for years, become infected, and may lead to an eventual need for an amputation.

At Valley Foot Surgeons, Phoenix Top Doc Richard Jacoby is now offering stem cell treatments for diabetic wounds. These treatments are performed as an outpatient and involve subcutaneous injections of amniotic derived stem cell material around the wound.

The procedure offers several benefits in addition to a hefty concentration of stem cells. The material is immunologically privileged and does not cause a rejection reaction. It is processed from an FDA regulated lab.

The amniotic derived stem cells assists with the creation of new blood vessels to help heal the wounds and also contains a significant amount of growth factors. The stem cell material also has antimicrobial properties, helping avoid infection.

Along with the stem cell procedures, Valley Foot Surgeons offers laser treatment simultaneously which further helps with the healing process. With approximately 100 stem cell procedures performed so far for diabetic wounds, the outcomes have been nothing short of incredible.

Wounds have been healing, and much faster than with conventional methods. For more information and treatment with the top foot and ankle stem cell doctor in Phoenix and Scottsdale, call (480) 420-3499.

Read the original:
Top Phoenix Foot and Ankle Specialist, Valley Foot Surgeons, Now Offering Stem Cell Procedures for Healing Diabetic ...

stem cell therapy treatment for Global Developmental Delay with Severe Mental Retardation
improvement seen in just 3 months after stem cell therapy treatment for Global Developmental Delay with Severe Mental Retardation by dr alok sharma, mumbai, ...

By: Neurogen Brain and Spine Institute

Go here to see the original:
stem cell therapy treatment for Global Developmental Delay with Severe Mental Retardation - Video

stem cell therapy treatment for cerebral palsy with mental retardation with low vision by dr alok
improvement seen in just 3 months after stem cell therapy treatment for cerebral palsy with mental retardation with low vision by dr alok sharma, mumbai, ind...

By: Neurogen Brain and Spine Institute

Originally posted here:
stem cell therapy treatment for cerebral palsy with mental retardation with low vision by dr alok - Video

Marie McCullough, Inquirer Staff Writer Last updated: Sunday, April 20, 2014, 8:51 AM Posted: Saturday, April 19, 2014, 4:05 PM

Mason Shaffer was seven months old when doctors treated him for a fatal genetic bone disorder by destroying his blood and immune systems and rebuilding them with donated blood stem cells.

That's when his parents, Sarah and Marc Shaffer of Lansdowne, learned about a fairly unsung medical trend: public, nonprofit facilities that collect, store, and distribute blood from donated umbilical cords. The stem cells that saved Mason, now a healthy 5-year-old, were in cord blood.

Nonprofit cord-blood banking is a complicated, costly network, but it has been growing steadily, thanks to federal support, stem-cell research - and families like the Shaffers.

Sarah and Marc discovered that in the Philadelphia area, even if parents realized umbilical cords were more than just waste products of childbirth, there was no easy way to donate the tissue. So they established the Mason Shaffer Foundation to change that.

This month, Temple University Hospital launched a program in collaboration with the foundation and the New Jersey Cord Blood Bank to educate expectant parents and enable them to donate in a convenient way - at no charge to them or Temple. The foundation provides the educational material, and the cord-blood bank covers the collection costs, which are offset by health insurance reimbursement for transplants.

Three years ago, Lankenau Medical Center in Wynnewood became the foundation's first cord-blood donation center.

Temple, however, is expected to help fill the desperate need for a more racially diverse cord-blood stockpile. That need was recognized by the federal Stem Cell Therapeutic and Research Act of 2005, which included funding that will help underwrite the first year of Temple's program.

Of the 3,200 babies delivered at Temple each year, 65 percent are African American, and 30 percent are Hispanic.

Read more here:
Umbilical cord blood transplants become standard

Ever since Dolly the Sheep was cloned in 1996, scientists have been trying to do the same thing with human cells. Using the same technique, scientists say they've finally accomplished the feat with adult cells.

"What we show for the first time is that you can actually take skin cells, from a middle-aged 35-year-old male, but also from an elderly, 75-year-old male" and use the DNA to create tissue with cells of an exact match, said co-author of the study Robert Lanza.

The work was published in the journal Cell Stem Cell.

Last year, the technique was successfully used with infant cells, but in order to create tissue in a lab that could treat adult diseases, such as Alzheimer's, scientists needed to know if the technique would work with adult cells.

"I'm happy to hear that our experiment was verified and shown to be genuine," said Shoukhrat Mitalipov, a development biologist at Oregon Health and Science University, who led the 2013 study.

The work confirmed that starting with a quality human egg is key to the process. The researchers replaced the original DNA in an unfertilized egg with the donor DNA, and then cultured the cells in a lab dish. The stem cells, which were an exact match to the donor's DNA, can then be turned into various tissue types.

Even though full human cloning is a long way off, the report may raise an equal amount of concern and excitement.

"Certainly this kind of technology could be abused by some kind of rogue scientist," Paul Knoepfler of the University of California, Davis, School of Medicine, told NPR.

Follow this link:
Adult Human Cells Cloned for First Time

PUBLIC RELEASE DATE:

20-Apr-2014

Contact: Krista Conger kristac@stanford.edu 650-725-5371 Stanford University Medical Center

STANFORD, Calif. A single type of cell in the lining of the bladder is responsible for most cases of invasive bladder cancer, according to researchers at the Stanford University School of Medicine.

Their study, conducted in mice, is the first to pinpoint the normal cell type that can give rise to invasive bladder cancers. It's also the first to show that most bladder cancers and their associated precancerous lesions arise from just one cell, and explains why many human bladder cancers recur after therapy.

"We've learned that, at an intermediate stage during cancer progression, a single cancer stem cell and its progeny can quickly and completely replace the entire bladder lining," said Philip Beachy, PhD, professor of biochemistry and of developmental biology. "All of these cells have already taken several steps along the path to becoming an aggressive tumor. Thus, even when invasive carcinomas are successfully removed through surgery, this corrupted lining remains in place and has a high probability of progression."

Although the cancer stem cells, and the precancerous lesions they form in the bladder lining, universally express an important signaling protein called sonic hedgehog, the cells of subsequent invasive cancers invariably do not a critical switch that appears vital for invasion and metastasis. This switch may explain certain confusing aspects of previous studies on the cellular origins of bladder cancer in humans. It also pinpoints a possible weak link in cancer progression that could be targeted by therapies.

"This could be a game changer in terms of therapeutic and diagnostic approaches," said Michael Hsieh, MD, PhD, assistant professor of urology and a co-author of the study. "Until now, it's not been clear whether bladder cancers arise as the result of cancerous mutations in many cells in the bladder lining as the result of ongoing exposure to toxins excreted in the urine, or if it's due instead to a defect in one cell or cell type. If we can better understand how bladder cancers begin and progress, we may be able to target the cancer stem cell, or to find molecular markers to enable earlier diagnosis and disease monitoring."

Beachy is the senior author of the study, which will be published online April 20 in Nature Cell Biology. He is the Ernest and Amelia Gallo Professor in the School of Medicine and a member of the Stanford Cancer Institute and the Stanford Institute for Stem Cell Biology and Regenerative Medicine. He is also a Howard Hughes Medical Institute investigator. Kunyoo Shin, PhD, an instructor at the institute, is the lead author.

Bladder cancer is the fourth most common cancer in men and the ninth most common in women. Smoking is a significant risk factor. There are two main types of the disease: one that invades the muscle around the bladder and metastasizes to other organs, and another that remains confined to the bladder lining. Unlike the more-treatable, noninvasive cancer which comprises about 70 percent of bladder cancers the invasive form is largely incurable. It is expensive and difficult to treat, and the high likelihood of recurrence requires ongoing monitoring after treatment.

The rest is here:
Stanford scientists identify source of most cases of invasive bladder cancer

Ankle arthritis; 4 months after stem cell therapy by Dr Harry Adelson
Craig discusses his results from his stem cell therapy by Dr Harry Adelson for his arthritic ankle http://www.docereclinics.com.

By: Harry Adelson, N.D.

More here:
Ankle arthritis; 4 months after stem cell therapy by Dr Harry Adelson - Video

Scientists have moved a step closer to the goal of creating stem cells perfectly matched to a patient's DNA in order to treat diseases, they announced on Thursday, creating patient-specific cell lines out of the skin cells of two adult men.

The advance, described online in the journal Cell Stem Cell, is the first time researchers have achieved "therapeutic cloning" of adults. Technically called somatic-cell nuclear transfer, therapeutic cloning means producing embryonic cells genetically identical to a donor, usually for the purpose of using those cells to treat disease.

But nuclear transfer is also the first step in reproductive cloning, or producing a genetic duplicate of someone - a technique that has sparked controversy since the 1997 announcement that it was used to create Dolly, the clone of a ewe. In 2005, the United Nations called on countries to ban it, and the United States prohibits the use of federal funds for either reproductive or therapeutic cloning.

The new study was funded by a foundation and the South Korean government.

If confirmed by other labs, it could prove significant because many illnesses that might one day be treated with stem cells, such as heart failure and vision loss, primarily affect adults. Patient-specific stem cells would have to be created from older cells, not infant or fetal ones. That now looks possible, though far from easy: Out of 39 tries, the scientists created stem cells only once for each donor.

Outside experts had different views of the study, which was led by Young Gie Chung of the Research Institute for Stem Cell Research at CHA Health Systems in Los Angeles.

Stem cell biologist George Daley of the Harvard Stem Cell Institute called it "an incremental advance" and "not earth-shattering."

Reproductive biologist Shoukhrat Mitalipov of Oregon Health and Science University, who developed the technique the CHA team adapted, was more positive. "The advance here is showing that (nuclear transfer) looks like it will work with people of all ages," he said in an interview.

A year ago, Mitalipov led the team that used nuclear transfer of fetal and infant DNA to produce stem cells, the first time that had been accomplished in humans of any age.

ELECTRIC JOLT

Original post:
In a cloning first, scientists create stem cells from ...

A breakthrough in human stem cell research could lead to the treatment of countless diseases, invaluable scientific research and yes, human cloning.

According to a study in the journalCell Stem Cell, scientists have synthesized human embryonic stem cells from the cells of adults, creating two different lines from the skin of two donors.

>> Read more trending stories

Using the nuclear transfermethod,scientists took DNA out of egg cells and replaced it with the donor DNA. The cells were basically reprogrammed, butof the 77 samplesonly two fully developed into cloned stem cells.

Lead researcher Robert Lanza says the 5 percent success rate isn't surprising."Reprogramming is more difficult for adult cells than for fetal [and] infant cells, presumably at least in part because their epigenetic landscape from the pluripotent state,"meaning the cells generally dont' have the right enzymes for change anymore.

The researchers reportedly tweaked a method made famous by the cloning of the sheep Dolly in 1996 and improved by scientists at Oregon Health & Science University just last year.

The nuclear transfermethod is the third discovered way to harvest or create stem cells. In the past, scientists have extracted cells from leftover embryos after in vitro fertilizations,a controversial practice. And in 2006 aJapanese researcher discovered a way to create themby injecting new genes. (ViaAsian Scientist)

Lanza's method could provide easy access to stem cells, opening up new research intodiseases like diabetes, Parkinsons and even leukemia. And according toNPR, the researcher wants to create a virtual library of cells using carefully selected DNA donors.

The implications of a real and viable approach for creating stem cells could be startling, andscientists have been wrestling with the ethical questions since the cloning of Dolly.

An official at Oregon Health & Science Universitythinks studying stemcells is necessary, tellingTime,They have become kind of like cursed cells. But we clearly need to understand more about them.

View post:
Scientists create stem cells from adult skin cells

April 18, 2014

Brett Smith for redOrbit.com Your Universe Online

In a significant breakthrough a team of scientists from California and Seoul, South Korea have been able to create viable stem cells from an adult donor that perfectly match the donors DNA, according to a new report in the journal Cell Stem Cell.

The development, referred to as therapeutic cloning, involves the production of embryonic cells for scientific purposes and many object to this type of research based on moral or religious grounds. Debate over this type of work was stoked in 1997 with the announcement that it was used to create the clone of a sheep, called Dolly. In 2005, the United Nations called for a ban on cloning and the United States government currently prohibits the use of federal dollars for cloning research.

The scientists behind the latest development, which was partially funded by the government of South Korea, acknowledged that if the embryos in their study were implanted in a uterus they could have developed into a fetus.

Without regulations in place, such embryos could also be used for human reproductive cloning, although this would be unsafe and grossly unethical, study author Dr. Robert Lanza, chief scientist of Massachusetts-based biotech Advanced Cell Technology, told Reuters reporter Sharon Begley.

To produce viable stem cells from an adult donor, the researchers first inserted DNA from an adult skin cell into a donated ovum. The scientists then delivered an electric shock to fuse the genetic material to the ovum. Eventually, the ovum divides and multiplies becoming a viable embryo in five or six days. Pluripotent stem cells, which can become any type of cell in the body, are located on the interior of this embryo.

Last year, a team of Oregon scientists reported on their success in combining genetic material from fetal and infant cells with DNA-extracted eggs. The team was able to develop their eggs into approximately 150-cell embryos.

The Oregon team said a major aspect of their success was allowing the engineered eggs to sit for 30 minutes before hitting them with the charge of electricity that like Dr. Frankensteins monster set the eggs on the path to becoming alive.

In the new study, the researchers waited two hours before triggering the egg, which Lanza said allowed them to succeed.

Go here to read the rest:
Stem Cells Created From Adult Cells

Scientists have replicated one of the most significant accomplishments in stem cell research by creating human embryos that were clones of two men.

The lab-engineered embryos were harvested within days and used to create lines of infinitely reproducing embryonic stem cells, which are capable of growing into any type of human tissue.

The work, reported Thursday in the journal Cell Stem Cell, comes 11 months after researchers in Oregon said they had produced the world's first human embryo clones and used them to make stem cells. Their study, published in Cell, aroused skepticism after critics pointed out multiple errors and duplicated images.

In addition, the entire effort to clone human embryos and then dismantle them in the name of science troubles some people on moral grounds.

MORE: Medicines and machines, inspired by nature

The scientists in Oregon and the authors of the new report acknowledged that the clones they created could develop into babies if implanted in surrogate wombs. But like others in the field, they have said reproductive cloning would be unethical and irresponsible.

The process used to create cloned embryos is called somatic cell nuclear transfer, or SCNT. It involves removing the nucleus from an egg cell and replacing it with a nucleus from a cell of the person to be cloned. The same method was used to create Dolly the sheep in 1996, along with numerous animals from other species.

Human cloning was a particular challenge, in part because scientists had trouble getting enough donor eggs to carry out their experiments. Some scientists said SCNT in humans would be impossible.

Dr. Robert Lanza, the chief scientific officer for Advanced Cell Technology Inc. in Marlborough, Mass., has been working on SCNT off and on for about 15 years. He and his colleagues finally achieved success with a modified version of the recipe used by the Oregon team and skin cells donated by two men who were 35 and 75.

After swapping out the nucleus in the egg cell, both groups used caffeine to delay the onset of cell division a technique that has been called "the Starbucks effect." But instead of waiting 30 minutes to prompt cell division, as was done in the Oregon experiment, Lanza and his team waited two hours.

See the article here:
Scientists use cloning to make stem cells matched to two adults